tag:blogger.com,1999:blog-4241416962008169508.post8119541844322529842..comments2024-03-27T21:03:58.972-04:00Comments on Just A Life Sciences Blog...: BREAKING: Schering-Plough Just Disclosed the Full "Merial-Sanofi-Intervet Call" AgreementUnknownnoreply@blogger.comBlogger1125tag:blogger.com,1999:blog-4241416962008169508.post-89141911657533331582009-07-31T18:48:05.494-04:002009-07-31T18:48:05.494-04:00Update on asenapine.
The background package shows...Update on asenapine.<br /><br />The background package shows the reviewer asked that the metabolites be properly identified and tested for phen-fen like pharmacology (agonism at the 5HT2B receptor).<br /><br />The reviewer then disappears and someone else claims the metabolites were adequately identified when they weren't. It also looks like FDA management refused to even look into the receptor binding of the metabolites and they only talk about the effects of asenapine itself at receptors.<br /><br />Even a screen of the most important metabolites should have only taken a few days. Identifying and testing all the metabolites could have been done during the past year.<br /><br />Something similar happened with Phen-Fen. They had tested the metabolites internally and knew it was the metabolites that were toxic but didn't report the results to the FDA. <br /><br />Looks like very suspicious to me.<br /><br />SalmonAnonymousnoreply@blogger.com